QR Pharma, headquartered in Berwyn, Pennsylvania, is a clinical-stage specialty pharmaceutical company focused on novel therapeutics for cognitive impairment in neurological disorders. Its lead compound, Posiphen, is described as neuroprotective and is reported to inhibit synthesis of neurotoxic aggregating proteins to protect nerve cells. The company plans to use the new funding to continue development of Posiphen, build a pipeline, and support completion of a phase II clinical study in Alzheimer's patients. QR has completed animal studies in Alzheimer's and Parkinson's disease models and is expanding Posiphen's application to Huntington's disease, glaucoma, and traumatic brain injury. Non-equity funding noted in the article includes $2M from the NIH for a phase II study and a $3M award from the U.S. Army for traumatic brain injury work. QR Pharma is a clinical-stage specialty pharmaceutical company headquartered in Berwyn, Pennsylvania, focused on developing therapeutics for cognitive impairment in neurological disorders. Its lead compound, Posiphen, is described as a neuroprotective agent that inhibits synthesis of neurotoxic aggregating proteins to protect nerve cells. QR has completed animal studies in Alzheimer’s and Parkinson’s disease models and is expanding Posiphen’s application to Huntington’s, glaucoma and traumatic brain injury. The company also has a second program, BNC, for advanced Alzheimer’s disease. QR was awarded $3M from the US Army for work in traumatic brain injury and has been selected by the NIH for a human Phase II clinical trial in Alzheimer’s patients. The company says it will use the recent financing to study Posiphen in additional indications and to support completion of a Phase II Alzheimer’s study. QR Pharma is a specialty pharmaceutical company based in Berwyn, Pennsylvania, developing novel treatments for neurodegenerative disorders. Its lead candidate, Posiphen®, is in clinical development targeting early-stage Alzheimer’s and Parkinson’s disease to stop or slow progression. The company is also advancing BNC, a program aimed at stabilizing decline in late-stage Alzheimer’s. QR Pharma focuses on therapies for Alzheimer’s, Parkinson’s and other neurodegenerative disorders. Financially, the company has received investments from Ben Franklin Technology Partners of Southeastern Pennsylvania, including a recent $110K follow-on and a prior $500K investment. Maria Maccecchini, Ph.D., is Founder, CEO & President, and John Bennett is COO. QR Pharma is a Radnor, Pennsylvania–based specialty pharmaceutical company focused on developing novel therapeutics to treat Alzheimer’s disease and cognitive impairment. Its pipeline centers on two compound programs: Posiphen® and Bisnorcymserine (BNC). The company plans to advance clinical development of both programs. QR opened a seed financing round a year earlier and has now closed commitments totaling $2.4M. Named investors include BioAdvance, Ben Franklin Technology Partner and undisclosed business angels alongside other private investor funds. The capital infusion will support the clinical development activities for the Posiphen and BNC programs.

Total raised

$7M

Funding rounds

4

Latest round

Series A

Latest activity

Oct 2016